Synerrv Atorvastatin Side Effects

The following are the adverse reaction profile for Atorvastatin: Infections and infestations: Common: nasopharyngitis.
Blood and lymphatic system disorders: Rare: thrombocytopenia.
Immune system disorders: Common: allergic reactions. Very rare: anaphylaxis.
Metabolism and nutrition disorders: Common: hyperglycaemia. Uncommon: hypoglycaemia, weight gain, anorexia.
Psychiatric disorders: Uncommon: nightmare, insomnia.
Nervous system disorders: Common: headache. Uncommon: dizziness, paraesthesia, hypoesthesia, dysgeusia, amnesia. Rare: peripheral neuropathy.
Eye disorders: Uncommon: vision blurred. Rare: visual disturbance.
Ear and labyrinth disorders: Uncommon: tinnitus. Very rare: hearing loss.
Respiratory, thoracic and mediastinal disorders: Common: pharyngolaryngeal pain, epistaxis.
Gastrointestinal disorders: Common: constipation, flatulence, dyspepsia, nausea, diarrhoea. Uncommon: vomiting, abdominal pain upper and lower, eructation, pancreatitis.
Hepatobiliary disorders: Uncommon: hepatitis. Rare: cholestasis. Very rare: hepatic failure.
Skin and subcutaneous tissue disorders: Uncommon: urticaria, skin rash, pruritus, alopecia. Rare: angioneurotic oedema, dermatitis bullous including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Musculoskeletal and connective tissue disorders: Common: myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain. Uncommon: neck pain, muscle fatigue. Rare: myopathy, myositis, rhabdomyolysis, tendinopathy, sometimes complicated by rupture. Not known: immune mediated necrotizing myopathy.
Reproductive system and breast disorders: Very rare: gynecomastia.
General disorders and administration site conditions: Uncommon: malaise, asthenia, chest pain, peripheral oedema, fatigue, pyrexia.
There have been rare post-marketing reports of cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally non-serious and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median 3 weeks).
Increases in HbA1c and fasting blood glucose have been reported with statins. The risk of hyperglycemia, however, is outweighed by the reduction in vascular risk with statins.